SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Olsson Anna S. B.)
 

Search: WFRF:(Olsson Anna S. B.) > (2020-2024) > Impact of type of r...

  • Ahmed, SairahUniv Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. (author)

Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-04-21
  • WILEY,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-422474
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422474URI
  • https://doi.org/10.1111/bjh.16664DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143442382URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Reduced-intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo-HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular conditioning regimen. We analyzed 492 adult patients undergoing human leucocyte antigen (HLA)-matched sibling or unrelated donor allo-HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan (Flu/Bu), fludarabine/melphalan (Flu/Mel140) or fludarabine/cyclophosphamide (Flu/Cy). Multivariable regression analysis was performed using a significance level of <0 center dot 01. There were no significant differences between regimens in risk for non-relapse mortality (NRM) (P = 0 center dot 54), relapse/progression (P = 0 center dot 02) or progression-free survival (PFS) (P = 0 center dot 14). Flu/Cy conditioning was associated with decreased risk of mortality in the first 11 months after allo-HCT (HR = 0 center dot 28; 95% CI = 0 center dot 10-0 center dot 73; P = 0 center dot 009), but beyond 11 months post allo-HCT it was associated with a significantly higher risk of mortality, (HR = 2 center dot 46; 95% CI = 0 center dot 1.32-4 center dot 61; P = 0 center dot 005). Four-year adjusted overall survival (OS) was similar across regimens at 62% for Flu/Bu, 59% for Flu/Mel140 and 55% for Flu/Cy (P = 0 center dot 64), respectively. These data confirm the choice of RIC for allo-HCT in HL does not influence risk of relapse, NRM or PFS. Although no OS benefit was seen between Flu/Bu and Flu/Mel 140; Flu/Cy was associated with a significantly higher risk of mortality beyond 11 months from allo-HCT (possibly due to late NRM events).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ghosh, NilanjanAtrium Hlth, Levine Canc Inst, Hematol Oncol & Blood Disorders, Charlotte, NC USA. (author)
  • Ahn, Kwang W.Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Khanal, ManojMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (author)
  • Litovich, CarlosMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (author)
  • Mussetti, AlbertoInst Catal Oncol Hosp, Hematol Dept, Barcelona, Spain.;Hosp Llobregat, IDIBELL Inst Catala Oncol, El Prat De Llobregat, Spain. (author)
  • Chhabra, SaurabhMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA. (author)
  • Cairo, MitchellNew York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA. (author)
  • Mei, MatthewCity Hope Natl Med Ctr, Duarte, CA USA. (author)
  • William, BasemOhio State Univ, Div Hematol, Columbus, OH 43210 USA. (author)
  • Nathan, SunitaRush Univ, Med Ctr, Chicago, IL 60612 USA. (author)
  • Bejanyan, NelliH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA. (author)
  • Olsson, RichardUppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677 (author)
  • Dahi, Parastoo B.Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA. (author)
  • van der Poel, MarjoleinMaastricht Univ, Med Ctr, Maastricht, Netherlands. (author)
  • Steinberg, AmirMt Sinai Hosp, Div Hematol & Oncol, New York, NY 10029 USA. (author)
  • Kanakry, JenniferNCI, NIH, Bethesda, MD 20892 USA. (author)
  • Cerny, JanUniv Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA. (author)
  • Farooq, UmarUniv Iowa Hosp & Clin, Div Hematol, Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA. (author)
  • Seo, SachikoDokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan. (author)
  • Kharfan-Dabaja, Mohamed A.Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL 32224 USA. (author)
  • Sureda, AnnaUniv Barcelona, Inst Catal Oncol Hosp, Hematol Dept, IDIBELL, Barcelona, Spain. (author)
  • Fenske, Timothy S.Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA. (author)
  • Hamadani, MehdiMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA. (author)
  • Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.Atrium Hlth, Levine Canc Inst, Hematol Oncol & Blood Disorders, Charlotte, NC USA. (creator_code:org_t)

Related titles

  • In:British Journal of Haematology: WILEY190:4, s. 573-5820007-10481365-2141

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view